NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2023 after the close of the U.S. financial markets on November 8, 2023 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
| Date: | Wednesday, November 8th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 1-877-704-4453 |
| International Dial-In: | 1-201-389-0920 |
| Conference ID: | 13741419 |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.05 |
| Daily Change: | -0.25 -1.75 |
| Daily Volume: | 1,542,371 |
| Market Cap: | US$592.770M |
May 22, 2025 April 28, 2025 March 10, 2025 March 06, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
